It is widely believed that the hypermethylation of the SFRP2 promoter and co-hypermethylation of SFRP1 and SFRP2 may serve as independent prognostic predictors of survival advantage in CRC patients post-surgery. The gene discussed is SFRP2; the disease is colorectal carcinoma.